Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 6/20 | 0.73 |
| ▸ | GRIN2B | Q13224 | 8/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18362071 | 0.86 | LOXL2 (0.52) | LOXL2KDM4EALDH1A1 | |
| SCHEMBL18362031 | 0.84 | LOXL2 (1.00) | LOXL2GRIN2BKDM4EALDH1A1TSHR | |
| SCHEMBL19755759 | 0.80 | LOXL2 (0.77) | LOXL2GRIN2BKDM4EALDH1A1TSHR | |
| SCHEMBL18361808 | 0.80 | LOXL2 (0.45) | LOXL2ALDH1A1L3MBTL1 | |
| SCHEMBL18361832 | 0.79 | LOXL2 (0.44) | LOXL2 | |
| SCHEMBL18049227 | 0.79 | LOXL2 (0.74) | LOXL2GRIN2BKDM4EALDH1A1TSHR | |
| SCHEMBL20337881 | 0.79 | ALDH1A1 (0.49) | LOXL2GRIN2BALDH1A1LMNA | |
| SCHEMBL18050008 | 0.78 | LOXL2 (1.00) | LOXL2GRIN2BKDM4EALDH1A1TSHR | |
| Hydrochloric Acid SCHEMBL18049099 | 0.78 | LOXL2 (0.73) | LOXL2GRIN2BKDM4EALDH1A1TSHR | |
| SCHEMBL18362172 | 0.76 | LOXL2 (0.42) | LOXL2ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180186755-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA INC (US) | 2018-07-05 | — | — | US | disclosed |
| US-20180186755-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA INC (US) | 2018-07-05 | — | — | US | disclosed |
| US-20180186755-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA INC (US) | 2018-07-05 | — | — | US | disclosed |
| WO-2017003862-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA, INC. (US) | 2017-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180186755-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | LOXL2, LOXL1, LOX | LOXL2 1/4885GRIN2B 3182/4885KDM4E 1498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.